On Friday, Crossject announced the appointment of Daniel Teper, a US-based pharmaceutical executive, to its Supervisory Board, with the aim of expanding into the US market.

The French company, the originator of a patented needle-free auto-injection system, stresses that this appointment comes at a 'key' moment for the company, i.e. against the backdrop of its transition as a specialist pharmaceutical laboratory in the USA.

Crossject hopes that the arrival of the businessman will help it achieve its growth objectives, in particular by contributing to the success of Zeneo, its needle-free auto-injection system, across the Atlantic.

Daniel Teper began his career at Novartis headquarters in Basel, where he quickly acquired increasing responsibilities in sales, marketing and new product development in the USA.

After returning to Europe, he held a sales position at Glaxo, before becoming a partner at EuroRSCG Havas Santé, where he advised major pharmaceutical groups on the launch of several drugs.

He is currently Managing Director of Cytovia Therapeutics.

Crossject's technology will make it the world leader in self-administered emergency medication for epilepsy, overdose, allergic shock, severe migraine and asthma attacks.

Copyright (c) 2023 CercleFinance.com. All rights reserved.